News | November 09, 2012

D3 Completes More Than 30,000 Advanced Treatment Plans, Commissions 100th Linear Accelerator

d3 logo

November 9, 2012 — The team of dosimetrists and physicists at D3 Oncology Solutions (D3), an affiliate of UPMC and UPMC CancerCenter, recently surpassed significant milestones: completing its 30,000th advanced treatment plan and commissioning its 100th linear accelerator.

"These milestones are significant for us because they reflect the continued confidence of our customers in the quality and efficiency of D3's services," said Kathy Lokay, president and CEO of D3.

Richard Lansberry, treatment planning manager, said, "D3 sets the industry standard for advanced treatment planning. Our core capabilities for centralized planning have been extended into the market through our training programs that help dosimetrists and physicists take their planning techniques to the next level of productivity and quality."

The collaborative nature of the training program can also be seen in other D3 services. From peer review to preparation for accreditation, to adoption of new technologies, D3's service model is bringing expertise to practices to enable local staff to confidently use advanced radiation techniques. An example is D3's Facilitated Commissioning product, which allows a local physicist to partner in the commissioning of a new linear accelerator, gaining first-hand experience at a lower cost while utilizing D3's expertise and proprietary tools.    

One of the key drivers of this collaborative commissioning approach was D3's development of their Diamond Dataset — the industry's first comprehensive catalogue of commissioning data from over 50 linear accelerators. By using this database, D3's physicists are able to significantly reduce the amount of data necessary to commission a new unit with no loss in the accuracy of the final beam models.  Results presented at the 2011 American Association of Physicists in Medicine (AAPM) conference confirmed that the Diamond Dataset dose models were within 1 percent of dose models generated from full commissioning data.

For more information: www.d3onc.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve